• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾动脉狭窄患者肾功能的决定因素。

Determinants of renal function in patients with renal artery stenosis.

机构信息

University of Toledo, OH, USA.

出版信息

Vasc Med. 2011 Oct;16(5):331-8. doi: 10.1177/1358863X11419998. Epub 2011 Sep 9.

DOI:10.1177/1358863X11419998
PMID:21908683
Abstract

Renal artery stenosis (RAS) is an important cause of renal failure; however, the factors associated with loss of kidney function in patients with RAS are poorly described, as are the predictors of an improvement in kidney function after stenting. One hundred patients at seven centers undergoing renal stenting were randomly assigned to an embolic protection device or double-blind use of a platelet glycoprotein IIb/IIIa inhibitor. The glomerular filtration rate (GFR) was measured using the creatinine-derived modified Modification of Diet in Renal Disease (MDRD) equation, cystatin C, and iohexol clearance. In univariate and multivariate models, baseline MDRD and cystatin C GFR were associated with congestive heart failure (CHF) (p = 0.01), lesion length (p = 0.01), and percent stenosis (-0.27, p = 0.01). In multivariate models, MDRD-estimated GFR 1 month after stenting was associated with bilateral stenosis (p < 0.05) and lesion length (p < 0.05), whereas with cystatin C the multivariate model included angiotensin receptor blocker (ARB) (p < 0.05) and minimal luminal diameter (MLD) (p < 0.05). The improvement in GFR from baseline to 1 month, measured as percent change, was related to baseline MDRD (p = 0.009) and cystatin C (p = 0.03) GFR. For MDRD GFR combined treatment with abciximab and Angioguard(®) embolic protection (p = 0.02) remained significant in multivariate analysis as did CHF, which was also significant with cystatin C (p = 0.05). In conclusion, CHF and lesion characteristics (MLD, percent stenosis and lesion length) are determinants of renal function in patients with RAS. In contrast, the acute improvement in renal function after revascularization is most strongly influenced by baseline GFR, and to a lesser degree CHF and combined procedural treatment with abciximab and embolic protection but not lesion characteristics. Clinical Trial Registration - URL:http://www.clinicaltrials.gov. Unique identifier: NCT00234585.

摘要

肾动脉狭窄 (RAS) 是肾功能衰竭的一个重要原因;然而,与 RAS 患者肾功能丧失相关的因素以及支架置入术后肾功能改善的预测因素描述得很差。在七个中心接受肾支架置入术的 100 名患者被随机分配到栓塞保护装置或血小板糖蛋白 IIb/IIIa 抑制剂的双盲使用。肾小球滤过率 (GFR) 使用肌酐衍生的改良肾脏病饮食修正公式 (MDRD)、胱抑素 C 和碘海醇清除率进行测量。在单变量和多变量模型中,基线 MDRD 和胱抑素 C GFR 与充血性心力衰竭 (CHF) (p = 0.01)、病变长度 (p = 0.01) 和狭窄程度 (-0.27,p = 0.01) 相关。在多变量模型中,支架置入术后 1 个月的 MDRD 估计 GFR 与双侧狭窄 (p < 0.05) 和病变长度 (p < 0.05) 相关,而胱抑素 C 的多变量模型包括血管紧张素受体阻滞剂 (ARB) (p < 0.05) 和最小管腔直径 (MLD) (p < 0.05)。从基线到 1 个月的 GFR 改善,以百分比变化表示,与基线 MDRD (p = 0.009) 和胱抑素 C (p = 0.03) GFR 相关。对于 MDRD GFR,联合使用阿昔单抗和 Angioguard®栓塞保护 (p = 0.02) 在多变量分析中仍然具有显著性,充血性心力衰竭也具有显著性,与胱抑素 C 相关 (p = 0.05)。总之,充血性心力衰竭和病变特征 (MLD、狭窄程度和病变长度) 是 RAS 患者肾功能的决定因素。相比之下,血管再通后肾功能的急性改善受基线 GFR 的影响最大,其次是充血性心力衰竭和联合使用阿昔单抗和栓塞保护的程序性治疗,但不受病变特征的影响。临床试验注册-网址:http://www.clinicaltrials.gov。独特标识符:NCT00234585。

相似文献

1
Determinants of renal function in patients with renal artery stenosis.肾动脉狭窄患者肾功能的决定因素。
Vasc Med. 2011 Oct;16(5):331-8. doi: 10.1177/1358863X11419998. Epub 2011 Sep 9.
2
Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy.保护肾动脉血管成形术和支架置入术中栓塞的预测因素:抗血小板治疗的作用。
Catheter Cardiovasc Interv. 2010 Jul 1;76(1):16-23. doi: 10.1002/ccd.22469.
3
Complete versus partial distal embolic protection during renal artery stenting.肾动脉支架置入术中完全与部分远端栓塞保护
Catheter Cardiovasc Interv. 2009 May 1;73(6):725-30. doi: 10.1002/ccd.21932.
4
Embolic protection and platelet inhibition during renal artery stenting.肾动脉支架置入术中的栓子保护与血小板抑制
Circulation. 2008 May 27;117(21):2752-60. doi: 10.1161/CIRCULATIONAHA.107.730259. Epub 2008 May 19.
5
Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure.胱抑素 C 水平在慢性收缩性心力衰竭患者肾功能和预后评估中的应用。
Heart. 2012 Feb;98(4):319-24. doi: 10.1136/heartjnl-2011-300692. Epub 2011 Oct 29.
6
Validation of a new plasma cystatin C-based formula and the Modification of Diet in Renal Disease creatinine-based formula for determination of glomerular filtration rate.一种基于血浆胱抑素C的新公式及肾脏病饮食改良研究中基于肌酐的公式用于测定肾小球滤过率的验证。
Scand J Urol Nephrol. 2009;43(3):242-9. doi: 10.1080/00365590902800738.
7
The management of renal artery atherosclerosis for renal salvage: does stenting help?为挽救肾脏而对肾动脉粥样硬化进行的管理:支架置入术有帮助吗?
J Vasc Surg. 2007 Jan;45(1):101-8; discussion 108-9. doi: 10.1016/j.jvs.2006.08.068.
8
Validity of estimated glomerular filtration rates for assessment of renal function after renal artery stenting in patients with atherosclerotic renal artery stenosis.估算肾小球滤过率评估动脉粥样硬化性肾动脉狭窄患者肾动脉支架置入术后肾功能的有效性。
JACC Cardiovasc Interv. 2014 May;7(5):543-9. doi: 10.1016/j.jcin.2013.11.021. Epub 2014 Apr 16.
9
Cystatin C identifies cardiovascular risk better than creatinine-based estimates of glomerular filtration in middle-aged individuals without a history of cardiovascular disease.胱抑素 C 比基于肌酐的肾小球滤过率估计在中年人群中更好地识别心血管风险,这些人群没有心血管疾病史。
J Intern Med. 2014 May;275(5):506-21. doi: 10.1111/joim.12169. Epub 2013 Dec 20.
10
Cystatin C in acute heart failure without advanced renal impairment.无晚期肾功能损害的急性心力衰竭患者中的胱抑素C
Am J Med. 2009 Jun;122(6):566-73. doi: 10.1016/j.amjmed.2008.10.042. Epub 2009 Apr 24.

引用本文的文献

1
Antiplatelet agents for chronic kidney disease.抗血小板药物在慢性肾脏病中的应用。
Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4.
2
Impact of Renal Function Trajectory on Renal Replacement Therapy and Mortality Risk after Renal Artery Revascularization.肾功能轨迹对肾动脉血运重建后肾脏替代治疗和死亡风险的影响。
J Vasc Interv Radiol. 2020 Apr;31(4):592-597. doi: 10.1016/j.jvir.2019.07.025. Epub 2019 Sep 14.
3
[Not Available].[无可用内容]。
J Vasc Bras. 2017 Apr-Jun;16(2):150-161. doi: 10.1590/1677-5449.010816.
4
Stenting and medical therapy for atherosclerotic renal-artery stenosis.经皮腔内血管成形术及药物治疗动脉粥样硬化性肾动脉狭窄
N Engl J Med. 2014 Jan 2;370(1):13-22. doi: 10.1056/NEJMoa1310753. Epub 2013 Nov 18.